
Travel Vaccines Market Report and Forecast 2024-2032
Description
Global Travel Vaccines Market Report and Forecast 2024-2032
The global travel vaccines market attained a value of about USD 3.87 billion in 2023. The market is expected to grow at a robust CAGR of 10.7% during the forecast period of 2024-2032, reaching nearly USD 9.67 billion by 2032. Theis growth is driven by the rising prevalence of infectious and travel-related diseases such as Japanese encephalitis, meningitis, diphtheria, and yellow fever, collectively fuelling the demand for effective vaccination solutions.
Global Travel Vaccines Market- Analysis
Travel vaccines are essential for protecting travellers from infectious diseases that may be prevalent in specific regions of the world. These vaccines are recommended based on the destination, duration of stay, and purpose of travel. With the rise in global travel, the demand for vaccines that prevent diseases such as hepatitis, yellow fever, and meningitis is increasing. The market is further supported by governmental and non-governmental health initiatives aimed at preventing the spread of infectious diseases across borders.
Market Drivers
Increasing Global Travel: The substantial rise in international travel for business, tourism, and education is a significant driver for the travel vaccines market. As more people venture into regions where endemic diseases are prevalent, the demand for vaccines to prevent illness intensifies, ensuring travellers remain protected during their journeys. This trend is particularly evident in regions with a high incidence of infectious diseases, where vaccination is often a prerequisite for entry or recommended by health authorities.
Governmental Health Initiatives: Governments around the world are increasingly implementing health policies that encourage or mandate vaccinations for travellers, particularly for diseases that pose substantial public health risks. These initiatives, often in the form of travel advisories or entry requirements, are significantly boosting the uptake of travel vaccines, contributing to public health safety and reducing the spread of infectious diseases across borders.
Advancements in Vaccine Technology: Technological advancements in vaccine development, particularly the creation of combination vaccines that protect against multiple diseases, are making vaccines more effective, safer, and convenient for travellers. These innovations are driving increased adoption, as they reduce the number of injections required and offer broader protection, thereby enhancing compliance among travellers who may otherwise avoid multiple vaccinations.
Market Challenges
Vaccine Hesitancy: Despite the availability and proven efficacy of vaccines, vaccine hesitancy remains a significant challenge. Misinformation and fear of side effects can deter travellers from getting vaccinated, impacting market growth.
Regulatory Hurdles: Navigating the complex regulatory landscape for vaccines in different countries can delay market entry and increase costs for vaccine manufacturers. Regulatory requirements vary widely, making compliance a significant challenge.
Logistical Challenges in Distribution: The distribution of vaccines, particularly to remote or underserved areas, can be challenging due to the need for cold chain storage and transportation. Ensuring that vaccines remain effective during transit is a critical concern.
Future Opportunities
Development of Universal Vaccines: Research into universal vaccines that offer protection against multiple strains or types of a virus presents a significant growth opportunity. Such vaccines could simplify travel health protocols and reduce the number of vaccinations required for international travel.
Technological Innovations in Vaccine Delivery: Innovations in vaccine delivery, such as needle-free options or oral vaccines, could increase vaccine uptake by making the vaccination process less invasive and more convenient for travellers.
Increasing Demand for Personalised Vaccination Plans: The growing demand for personalised healthcare extends to travel vaccines, with travellers seeking tailored vaccination plans based on their specific travel itinerary and health needs. This trend could drive the development of customised vaccine solutions.
Global Travel Vaccines Market Trends
Shift Towards Combination Vaccines: There is a growing trend towards the use of combination vaccines in the travel vaccines market. Combination vaccines offer protection against multiple diseases in a single dose, making them more convenient for travellers and increasing vaccination rates. This trend is particularly strong in regions where multiple vaccinations are required for safe travel, as it simplifies the vaccination process and reduces the number of injections needed.
Adoption of Digital Health Passports: With the ongoing digitalisation of healthcare, digital health passports that track vaccination status are becoming more common. These digital tools allow travellers to easily prove their vaccination status, facilitating smoother international travel and enhancing compliance with travel health regulations.
Increased Investment in Vaccine Research and Development: Governments and private organisations are increasing their investments in vaccine research and development, particularly in response to emerging global health threats. This trend is expected to drive the introduction of new and more effective travel vaccines over the coming years.
Expansion of Travel Health Clinics: The expansion of travel health clinics, particularly in urban centres and near major transportation hubs, is making it easier for travellers to access vaccines. These clinics often offer a one-stop solution for travel health needs, including vaccinations, travel advice, and health checks, contributing to the overall growth of the travel vaccines market.
Global Travel Vaccines Market Segmentation
Market Breakup by Composition
Mono Vaccines
Combination Vaccines
The market is segmented by composition into mono vaccines and combination vaccines. Mono vaccines are designed to protect against a single disease and remain widely used for their specific targeting capabilities. However, combination vaccines are increasingly popular due to their convenience, offering protection against multiple diseases in one shot. This segment is expected to see significant growth as it caters to the needs of travellers requiring multiple vaccinations, streamlining the immunisation process.
Market Breakup by Disease
Hepatitis A
DPT
Yellow Fever
Typhoid
Hepatitis B
Measles and Mumps
Rabies
Meningococcal
Others
The market segmentation of travel vaccines by disease includes hepatitis A, DPT, yellow fever, typhoid, hepatitis B, measles and mumps, rabies, meningococcal, and others. Hepatitis A and B vaccines are in high demand due to their effectiveness and the prevalence of these diseases in many travel destinations. Yellow fever and typhoid vaccines are also critical, especially for travellers to regions where these diseases are endemic. The 'others' category includes a range of vaccines for less common but equally important diseases, reflecting the diversity and complexity of travel health requirements.
Market Breakup by Region
North America
Europe
Asia Pacific
Latin America
Middle East and Africa
The market segmentation by region includes North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America leads the market, driven by high travel rates and strong healthcare infrastructure. Europe follows closely, with a well-established system for travel vaccination. The Asia Pacific region is experiencing rapid growth due to increasing outbound travel and rising awareness of travel-related health risks. Latin America the Middle East and Africa are emerging markets, with significant potential as international travel increases and healthcare infrastructure improves.
Global Travel Vaccines Market Competitive Landscape
The competitive landscape of the global travel vaccines market includes leading companies such as GlaxoSmithKline plc, Merck & Co., Sanofi SA, and Pfizer Inc., which dominate the market with extensive vaccine portfolios and strong global distribution networks. CSL Limited, Bavarian Nordic AS, and F. Hoffmann-La Roche Ltd are also key players, focusing on vaccine development and market expansion. Companies like Abbott Laboratories, AstraZeneca plc, and Janssen Pharmaceuticals contribute significantly to market growth through innovation and strategic partnerships. Valneva SE, BioNTech SE, and Sinovac Biotech Ltd are emerging players, enhancing competition and driving further advancements in the travel vaccines market.
Key Questions Answered in the Report
How is the global rise in travel influencing the demand for travel vaccines?
What role do governmental health initiatives play in boosting the uptake of travel vaccines?
How are advancements in vaccine technology impacting the travel vaccines market?
What are the primary challenges faced by vaccine manufacturers in the global travel vaccines market?
How does vaccine hesitancy affect the market growth for travel vaccines?
What opportunities exist for the development of universal travel vaccines?
How are technological innovations in vaccine delivery shaping the future of travel vaccinations?
What trends are driving the shift towards combination vaccines in the travel vaccines market?
How is the adoption of digital health passports influencing the travel vaccines industry?
What impact does the expansion of travel health clinics have on the availability of vaccines for travellers?
How are emerging markets such as Latin America and the Middle East contributing to the growth of the travel vaccines market?
What strategies are leading pharmaceutical companies using to maintain their competitive edge in the travel vaccines market?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the global travel vaccines market from 201724-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the global travel vaccines market.
The study maps the leading, as well as the fastest-growing, regional markets, enabling stakeholders to identify key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyse the level of competition within the global travel vaccines industry and its attractiveness.
The competitive landscape section allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market. *Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
200 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Travel Vaccines Market Overview
- 3.1 Global Travel Vaccines Market Historical Value (2017-2023)
- 3.2 Global Travel Vaccines Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Global Travel Vaccines Market Landscape*
- 5.1 Global Travel Vaccines Market: Developers Landscape
- 5.1.1 Analysis by Year of Establishment
- 5.1.2 Analysis by Company Size
- 5.1.3 Analysis by Region
- 5.2 Global Travel Vaccines Market: Product Landscape
- 5.2.1 Analysis by Composition
- 5.2.2 Analysis by Disease
- 6 Global Travel Vaccines Market Dynamics
- 6.1 Market Drivers and Constraints
- 6.2 SWOT Analysis
- 6.2.1 Strengths
- 6.2.2 Weaknesses
- 6.2.3 Opportunities
- 6.2.4 Threats
- 6.3 PESTEL Analysis
- 6.3.1 Political
- 6.3.2 Economic
- 6.3.3 Social
- 6.3.4 Technological
- 6.3.5 Legal
- 6.3.6 Environment
- 6.4 Porter’s Five Forces Model
- 6.4.1 Bargaining Power of Suppliers
- 6.4.2 Bargaining Power of Buyers
- 6.4.3 Threat of New Entrants
- 6.4.4 Threat of Substitutes
- 6.4.5 Degree of Rivalry
- 6.5 Key Demand Indicators
- 6.6 Key Price Indicators
- 6.7 Industry Events, Initiatives, and Trends
- 6.8 Value Chain Analysis
- 7 Global Travel Vaccines Market Segmentation (2017-2032)
- 7.1 Global Travel Vaccines Market (2017-2032) by Composition
- 7.1.1 Market Overview
- 7.1.2 Mono Vaccines
- 7.1.3 Combination Vaccines
- 7.2 Global Travel Vaccines Market (2017-2032) by Disease
- 7.2.1 Market Overview
- 7.2.2 Hepatitis A
- 7.2.3 DPT
- 7.2.4 Yellow Fever
- 7.2.5 Typhoid
- 7.2.6 Hepatitis B
- 7.2.7 Measles and Mumps
- 7.2.8 Rabies
- 7.2.9 Meningococcal
- 7.2.10 Others
- 7.3 Global Travel Vaccines Market (2017-2032) by Region
- 7.3.1 Market Overview
- 7.3.2 North America
- 7.3.3 Europe
- 7.3.4 Asia Pacific
- 7.3.5 Latin America
- 7.3.6 Middle East and Africa
- 8 North America Travel Vaccines Market (2017-2032)
- 8.1 North America Travel Vaccines Market (2017-2032) by Composition
- 8.1.1 Market Overview
- 8.1.2 Mono Vaccines
- 8.1.3 Combination Vaccines
- 8.2 North America Travel Vaccines Market (2017-2032) by Disease
- 8.2.1 Market Overview
- 8.2.2 Hepatitis A
- 8.2.3 DPT
- 8.2.4 Yellow Fever
- 8.2.5 Typhoid
- 8.2.6 Hepatitis B
- 8.2.7 Measles and Mumps
- 8.2.8 Rabies
- 8.2.9 Meningococcal
- 8.2.10 Others
- 8.3 North America Travel Vaccines Market (2017-2032) by Country
- 8.3.1 United States of America
- 8.3.2 Canada
- 9 Europe Travel Vaccines Market (2017-2032)
- 9.1 Europe Travel Vaccines Market (2017-2032) by Composition
- 9.1.1 Market Overview
- 9.1.2 Mono Vaccines
- 9.1.3 Combination Vaccines
- 9.2 Europe Travel Vaccines Market (2017-2032) by Disease
- 9.2.1 Market Overview
- 9.2.2 Hepatitis A
- 9.2.3 DPT
- 9.2.4 Yellow Fever
- 9.2.5 Typhoid
- 9.2.6 Hepatitis B
- 9.2.7 Measles and Mumps
- 9.2.8 Rabies
- 9.2.9 Meningococcal
- 9.2.10 Others
- 9.3 Europe Travel Vaccines Market (2017-2032) by Country
- 9.3.1 United Kingdom
- 9.3.2 Germany
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Others
- 10 Asia Pacific Travel Vaccines Market (2017-2032)
- 10.1 Asia Pacific Travel Vaccines Market (2017-2032) by Composition
- 10.1.1 Market Overview
- 10.1.2 Mono Vaccines
- 10.1.3 Combination Vaccines
- 10.2 Asia Pacific Travel Vaccines Market (2017-2032) by Disease
- 10.2.1 Market Overview
- 10.2.2 Hepatitis A
- 10.2.3 DPT
- 10.2.4 Yellow Fever
- 10.2.5 Typhoid
- 10.2.6 Hepatitis B
- 10.2.7 Measles and Mumps
- 10.2.8 Rabies
- 10.2.9 Meningococcal
- 10.2.10 Others
- 10.3 Asia Pacific Travel Vaccines Market (2017-2032) by Country
- 10.3.1 China
- 10.3.2 Japan
- 10.3.3 India
- 10.3.4 ASEAN
- 10.3.5 Australia
- 10.3.6 Others
- 11 Latin America Travel Vaccines Market (2017-2032)
- 11.1 Latin America Travel Vaccines Market (2017-2032) by Composition
- 11.1.1 Market Overview
- 11.1.2 Mono Vaccines
- 11.1.3 Combination Vaccines
- 11.2 Latin America Travel Vaccines Market (2017-2032) by Disease
- 11.2.1 Market Overview
- 11.2.2 Hepatitis A
- 11.2.3 DPT
- 11.2.4 Yellow Fever
- 11.2.5 Typhoid
- 11.2.6 Hepatitis B
- 11.2.7 Measles and Mumps
- 11.2.8 Rabies
- 11.2.9 Meningococcal
- 11.2.10 Others
- 11.3 Latin America Travel Vaccines Market (2017-2032) by Country
- 11.3.1 Brazil
- 11.3.2 Argentina
- 11.3.3 Mexico
- 11.3.4 Others
- 12 Middle East and Africa Travel Vaccines Market (2017-2032)
- 12.1 Middle East and Africa Travel Vaccines Market (2017-2032) by Composition
- 12.1.1 Market Overview
- 12.1.2 Mono Vaccines
- 12.1.3 Combination Vaccines
- 12.2 Middle East and Africa Travel Vaccines Market (2017-2032) by Disease
- 12.2.1 Market Overview
- 12.2.2 Hepatitis A
- 12.2.3 DPT
- 12.2.4 Yellow Fever
- 12.2.5 Typhoid
- 12.2.6 Hepatitis B
- 12.2.7 Measles and Mumps
- 12.2.8 Rabies
- 12.2.9 Meningococcal
- 12.2.10 Others
- 12.3 Middle East and Africa Travel Vaccines Market (2017-2032) by Country
- 12.3.1 Saudi Arabia
- 12.3.2 United Arab Emirates
- 12.3.3 Nigeria
- 12.3.4 South Africa
- 12.3.5 Others
- 13 Regulatory Framework
- 13.1 Regulatory Overview
- 13.2 US FDA
- 13.3 EU EMA
- 13.4 INDIA CDSCO
- 13.5 JAPAN PMDA
- 13.6 Others
- 14 Patent Analysis
- 14.1 Analysis by Type of Patent
- 14.2 Analysis by Publication Year
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Patent Age
- 14.5 Analysis by CPC Analysis
- 14.6 Analysis by Patent Valuation
- 14.7 Analysis by Key Players
- 15 Clinical Trial Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Grant Analysis
- 16.1 Analysis by Year
- 16.2 Analysis by Amount Awarded
- 16.3 Analysis by Issuing Authority
- 16.4 Analysis by Grant Product
- 16.5 Analysis by Funding Institute
- 16.6 Analysis by Departments
- 16.7 Analysis by Recipient Organization
- 17 Funding and Investment Analysis
- 17.1 Analysis by Funding Instances
- 17.2 Analysis by Type of Funding
- 17.3 Analysis by Funding Amount
- 17.4 Analysis by Leading Players
- 17.5 Analysis by Leading Investors
- 17.6 Analysis by Geography
- 18 Strategic Initiatives
- 18.1 Analysis by Partnership Instances
- 18.2 Analysis by Type of Partnership
- 18.3 Analysis by Leading Players
- 18.4 Analysis by Geography
- 19 Supplier Landscape
- 19.1 Market Share Analysis, By Region (Top 5 Companies)
- 19.1.1 Market Share Analysis: Global
- 19.1.2 Market Share Analysis: North America
- 19.1.3 Market Share Analysis: Europe
- 19.1.4 Market Share Analysis: Asia Pacific
- 19.1.5 Market Share Analysis: Others
- 19.2 GlaxoSmithKline plc
- 19.2.1 Financial Analysis
- 19.2.2 Product Portfolio
- 19.2.3 Demographic Reach and Achievements
- 19.2.4 Company News and Developments
- 19.2.5 Certifications
- 19.3 Merck & Co .
- 19.3.1 Financial Analysis
- 19.3.2 Product Portfolio
- 19.3.3 Demographic Reach and Achievements
- 19.3.4 Company News and Developments
- 19.3.5 Certifications
- 19.4 Sanofi SA
- 19.4.1 Financial Analysis
- 19.4.2 Product Portfolio
- 19.4.3 Demographic Reach and Achievements
- 19.4.4 Company News and Developments
- 19.4.5 Certifications
- 19.5 Pfizer Inc .
- 19.5.1 Financial Analysis
- 19.5.2 Product Portfolio
- 19.5.3 Demographic Reach and Achievements
- 19.5.4 Company News and Developments
- 19.5.5 Certifications
- 19.6 CSL Limited
- 19.6.1 Financial Analysis
- 19.6.2 Product Portfolio
- 19.6.3 Demographic Reach and Achievements
- 19.6.4 Company News and Developments
- 19.6.5 Certifications
- 19.7 Bavarian Nordic AS
- 19.7.1 Financial Analysis
- 19.7.2 Product Portfolio
- 19.7.3 Demographic Reach and Achievements
- 19.7.4 Company News and Developments
- 19.7.5 Certifications
- 19.8 F. Hoffmann-La Roche Ltd
- 19.8.1 Financial Analysis
- 19.8.2 Product Portfolio
- 19.8.3 Demographic Reach and Achievements
- 19.8.4 Company News and Developments
- 19.8.5 Certifications
- 19.9 Abbott Laboratories
- 19.9.1 Financial Analysis
- 19.9.2 Product Portfolio
- 19.9.3 Demographic Reach and Achievements
- 19.9.4 Company News and Developments
- 19.9.5 Certifications
- 19.10 AstraZeneca plc
- 19.10.1 Financial Analysis
- 19.10.2 Product Portfolio
- 19.10.3 Demographic Reach and Achievements
- 19.10.4 Company News and Developments
- 19.10.5 Certifications
- 19.11 Janssen Pharmaceuticals
- 19.11.1 Financial Analysis
- 19.11.2 Product Portfolio
- 19.11.3 Demographic Reach and Achievements
- 19.11.4 Company News and Developments
- 19.11.5 Certifications
- 19.12 Valneva SE
- 19.12.1 Financial Analysis
- 19.12.2 Product Portfolio
- 19.12.3 Demographic Reach and Achievements
- 19.12.4 Company News and Developments
- 19.12.5 Certifications
- 19.13 BioNTech SE
- 19.13.1 Financial Analysis
- 19.13.2 Product Portfolio
- 19.13.3 Demographic Reach and Achievements
- 19.13.4 Company News and Developments
- 19.13.5 Certifications
- 19.14 Sinovac Biotech Ltd
- 19.14.1 Financial Analysis
- 19.14.2 Product Portfolio
- 19.14.3 Demographic Reach and Achievements
- 19.14.4 Company News and Developments
- 19.14.5 Certifications
- 20 Global Travel Vaccines Market – Distribution Model (Additional Insight)
- 20.1 Overview
- 20.2 Potential Distributors
- 20.3 Key Parameters for Distribution Partner Assessment
- 21 Key Opinion Leaders (KOL) Insights (Additional Insight)
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- **The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.